| 000 | 01705 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516061950.0 | ||
| 264 | 0 | _c20120802 | |
| 008 | 201208s 0 0 eng d | ||
| 022 | _a1098-6596 | ||
| 024 | 7 |
_a10.1128/AAC.05710-11 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBeringer, Paul M | |
| 245 | 0 | 0 |
_aPharmacokinetics of doxycycline in adults with cystic fibrosis. _h[electronic resource] |
| 260 |
_bAntimicrobial agents and chemotherapy _cJan 2012 |
||
| 300 |
_a70-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aChromatography, Reverse-Phase |
| 650 | 0 | 4 |
_aCystic Fibrosis _xdrug therapy |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDoxycycline _xadministration & dosage |
| 650 | 0 | 4 |
_aExocrine Glands _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMatrix Metalloproteinase 9 _xmetabolism |
| 650 | 0 | 4 | _aMatrix Metalloproteinase Inhibitors |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aSputum _xchemistry |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aOwens, Heather | |
| 700 | 1 | _aNguyen, Albert | |
| 700 | 1 | _aBenitez, Debbie | |
| 700 | 1 | _aRao, Adupa | |
| 700 | 1 | _aD'Argenio, David Z | |
| 773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 56 _gno. 1 _gp. 70-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.05710-11 _zAvailable from publisher's website |
| 999 |
_c21256297 _d21256297 |
||